Prana Biotechnology (ATHE)
(Delayed Data from NSDQ)
$1.29 USD
-0.02 (-1.15%)
Updated Sep 17, 2024 03:05 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ATHE 1.29 -0.02(-1.15%)
Will ATHE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATHE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATHE
Alterity (ATHE) Up on Interim Data From Advance MSA Study
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
ATHE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
Other News for ATHE
Alterity Therapeutics Options Expire Unexercised
Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more
Alterity Therapeutics Options Expire Unexercised
Appendix 4C ? Q4 FY24 Quarterly Cash Flow Report
Alterity Therapeutics reports cash balance of A$12.6M as of June 30